Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05954858 · ClinicalTrials.gov registry record · NA
Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma
A NA study of Glioblastoma and Glioblastoma Multiforme, sponsored by Northwell Health.
- Recruiting
- Registry status
- NA
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT05954858: Recruiting NA study of Glioblastoma and Glioblastoma Multiforme, sponsored by Northwell Health.
NCT05954858 is a NA study of Glioblastoma and Glioblastoma Multiforme that is actively recruiting participants, run by Northwell Health. The registered enrollment target is 32 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05954858, a NA study of Glioblastoma and Glioblastoma Multiforme, is actively recruiting participants, sponsored by Northwell Health.
- RECRUITING
- Registry status
- NA
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
This single center, single arm, open-label, phase 2 study will assess the safety and efficacy of a pedicled temporoparietal fascial (TPF) or pericranial flap into the resection cavity of newly diagnosed glioblastoma multifome (GBM) patients. The objective of the Phase 2 study is to demonstrate that this surgical technique is safe and effective in a human cohort of patients with resected newly diagnosed AA or GBM and may improve progression-free survival (PFS) and overall survival (OS).
Primary Outcome
PFS is defined as time from surgery until first known disease progression or death from any cause, whichever occurs first.
Conditions Studied
Interventions
- PROCEDURE Tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap to bypass the blood brain barrier (BBB)
Study Locations (1)
New York
- Lenox Hill Brain Tumor Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2023-06-29 |
| Est. Completion | 2027-06-30 |
| Phase | NA |
What NCT05954858 shows while recruiting
NCT05954858 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (71% lower).
The record links to 7 conditions, with Glioblastoma appearing as the primary indexed condition, and to 1 intervention - of which Tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap to bypass the blood brain barrier (BBB) is the first listed.
NCT05954858 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05954858 about?
NCT05954858 is a clinical study titled "Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma". This single center, single arm, open-label, phase 2 study will assess the safety and efficacy of a pedicled temporoparietal fascial (TPF) or pericranial flap into the resection cavity of newly diagnosed glioblastoma multifome (GBM) patients. The objective of the Phase 2 study is to demonstrate that...
What is the current status of trial NCT05954858?
This trial is currently recruiting. It is a NA study. The enrollment target is 32 participants. The study started on 2023-06-29. Estimated completion is 2027-06-30.
What conditions does trial NCT05954858 study?
This clinical trial studies the following conditions: Glioblastoma, Glioblastoma Multiforme, Brain Cancer, High Grade Glioma, GBM.
What interventions are being tested in trial NCT05954858?
The interventions under investigation include: Tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap to bypass the blood brain barrier (BBB) (PROCEDURE).
Who is sponsoring clinical trial NCT05954858?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05954858 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05954858's enrollment target sits among peer trials
32 121st of 199 higher than 77 of 199 other Glioblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Glioblastoma Remote Monitoring and Care - Research Protocol
RECRUITING · NA
-
Evaluation of the CONVIVO System
RECRUITING · NA
-
Adaptive Radiotherapy and MRIs Based on Patients With Newly Diagnosed High-Grade Glioma
RECRUITING · NA
-
LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138)
RECRUITING · NA
-
Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors
RECRUITING · NA
-
Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI